Innovationsthat preservetheir possibilities

Behind every UroGen innovation is the inspiration to empower uro-oncology patients with life-changing treatments.

Welcome to UroGen®

UroGen has a steadfast commitment to elevating options for people living with urological cancers. With breakthrough technology we are able to break barriers to treatment, pioneering a future of new possibilities in transformative therapies.

Explore UroGen news

Nov 6, 2024

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

Read more

about UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

Nov 5, 2024

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

Read more

about UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 30, 2024

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

Read more

about UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

Oct 28, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Read more

about ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Oct 15, 2024

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Read more

about UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Oct 9, 2024

UroGen Appoints Chris Degnan as Chief Financial Officer

Read more

about UroGen Appoints Chris Degnan as Chief Financial Officer

Oct 2, 2024

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Read more

about First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Sep 16, 2024

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Read more

about UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Sep 5, 2024

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

about UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2024

UroGen Pharma to Present at Upcoming Investor Conferences

Read more

about UroGen Pharma to Present at Upcoming Investor Conferences

Our people are
passionate, progressive, and patient-driven